Price (delayed)
$23.33
Market cap
$2.56B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$3.24
Enterprise value
$2.26B
Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit high-value frontier targets in RAS-addicted cancers. The company possesses sophisticated structure-based drug discovery capabilities
There are no recent dividends present for RVMD.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.